Pt | Age | Cancer | Stage on enrollment | # of cycles | Off-study reason | PFS#(ms) | OS* (ms) | Immune response | |||
---|---|---|---|---|---|---|---|---|---|---|---|
Proliferative assay | Elispot | ||||||||||
 |  |  |  |  |  |  |  | Pre-vaccine | Post-vaccine | Pre-vaccine | Post-vaccine |
1B | 55 | Biliary | NED | 3 | PD | 2.9 | 8.7 | + | + | + | + |
2B | 33 | Colon | IV | 3 | PD | 2.9 | 16.9 | - | + | NA | |
3B | 51 | Colon | IV | 5 | PPS/Lost to follow-up | 9.2+ | 52.6 | + | + | - | + |
4B | 48 | Pancreatic | NED | 13 | Completed | 35.4+ | 35.4 | - | + | - | - |
5B | 51 | Colon | IV | 1 | PD | 1 | 1.5 | ND | |||
6B | 38 | Colon | IV | 1 | Refused further Tx | 0.2+ | 8.3 | ND | |||
7B | 60 | Pancreatic | IV | 3 | PD | 4.6 | 21 | - | - | NA | |
8B | 57 | Colon | IV | 3 | PD | 3.1 | 6.8 | NA | |||
9B | 52 | Colon | IV | 3 | PD | 3.3 | 28.3 | - | + | + | + |
10B | 58 | Pancreatic | IV | 3 | PD | 2.9 | 20.9 | + | + | - | + |
11B | 45 | Pancreatic | IV | 2 | PD | 1 | 7.3 | ND | |||
12B | 79 | Colon | IV | 3 | PPS | 12.9 | 42.1 | - | + | - | + |
13B | 43 | Colon | IV | 3 | PD | 2.6 | 6.3 | - | - | - | + |
14B | 78 | Colon | NED | 8 | Left voluntarily | 16.8 | 69 | - | + | - | + |
15B | 63 | Colon | IV | 3 | PD | 2.8 | 11.6 | + | + | - | + |
16B | 64 | Colon | IV | 6 | PD | 5.7 | 20.7 | - | + | - | - |
17B | 71 | Colon | IV | 6 | PD | 5.6 | 25.9 | - | + | - | + |
18B | 58 | Pancreatic | IV | 2 | PD | 2.6 | 3.3 | ND |